

Special Issue

New Advances in Lung Cancer: Diagnosis, Pathophysiology and Emerging Treatments. A Selection of Papers from the 4th Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)

Message from the Guest Editors

Lung cancer has become a paradigm for personalized medicine, where identifying disease subtypes through oncogenic driver mutations has led to the development of molecularly targeted therapies. Moreover, the impact of driver oncogenes on the immune tumor microenvironment has profound implications for the effectiveness of immune checkpoint inhibitors. New treatments such as antibody–drug conjugates (ADCs) could be used in the near future in lung cancer patients, alone or in combination with other therapeutic strategies. These new treatments should be associated with the development of predictive biomarkers. This Special Issue of *Cancers* focuses on recent topics of interest associated with lung cancer. This follows the 4th joint meeting between different physicians and researchers from both the MD Anderson Cancer Center (Houston, TX, USA), the FHU OncoAge (Nice, France), and the IHU RespirERA (Nice, France). The main objective of this Special Issue is to promote the recent understanding of the development of lung cancer, including new therapeutic strategies and new biomarkers.

Guest Editors

Prof. Dr. Paul Hofman
Dr. Ignacio I. Wistuba
Dr. John Heymach

Deadline for manuscript submissions

closed (28 February 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/202081

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)